


NeuroSafe

The technology of local brain cooling for World Healthcare



PRIORITIES OF WORLD HEALTHCARE


To solve the following problems:



Psychiatric disorders
Dementia
Alcoholism

55


million people are diagnosed with dementia worldwide*



Stroke
Traumatic brain injury

17

million people suffer from stroke each year*




Burden on the budget

700

billion (US dollars) treatment, rehabilitation, and indirect costs for stroke*

THE SOLUTION

The technology and equipment for brain cooling (craniocerebral hypothermia)



Controlled reduction/increase
of the cerebral cortex temperature
with NeuroSafe equipment

Increase of neuron tolerance
to ischemia, hypoxia,
reperfusion and trauma

Management of neurogenic fever
and cerebral hyperthermia

Prevention
of neurodegenerative processes

Increase
in physical performance



- Compact, portable model
- Compressor
- Cooling of one patient
- Weight (with coolant): 12 kg
- Cooling of the brain T0 no lower than 29°C
- Speed of brain cooling — 1°C in 45 min
- Time of the cooling of coolant from +25°C to 0°C: 20 min

*Craniocerebral therapeutic hypothermia
allows to extend the period of reversible brain damage
from 5 minutes to 45 minutes or more*

Stage of NeuroSafe development: beta testing

NeuroSafe is

an individual approach and widest range of application:

suitable for conscious state, coma, medical anesthesia

the safest and the most convenient method:

no pharmacological assistance required, no complications, no side effects

reduction of expenses at the hospital

the most effective hypothermia device on the market,
which has the **widest range of application**

the most attractive price for the equipment
and consumables on the market

cryoapplicators – reusable consumables

Nº1

in the world

Price/Quality
ratio
parameter

TARGET AUDIENCE

B2C

High income (private buyers)
Top athletes
Top Managers

The effect:

effective therapy and prevention
improved quality of life active
longevity
improved performance

B2G

Government hospitals

The effect:

Reduction of mortality by more than 30%
Improvement of the effectiveness of treatment
Reduction of hospitalization period
Decrease of budget costs for treatment of patients with cerebrovascular disease by 52% in year 1 (25 billion rubles) to 57% in year 4 (51 billion rubles)

B2B

Private hospitals

The effect:

the reduction of mortality by more than 30%*
improvement of treatment effectiveness
decrease of operating expenses for treatment of patients with cerebrovascular diseases (pharmacological support, decrease of hospitalization time) improved competitiveness

* Clinical trials: <http://cryotechnomed.com/therapeutic-hypothermia/>

STAGE

Pilot tests completed*, preparations for registration



Registered MVP

More than 5,000 patients were treated in Russia, Kazakhstan, and Uzbekistan with MVP



* **Multicentral research** in Russian clinics with MVP



Reviews from leading profile medical specialists in Russia*



Methodical medical recommendations

Application in emergency medicine, neurology, addiction medicine (RF)

6 Patents (RF) and application for PCT

Более 50 оригинальных работ в профильных изданиях (3 диссертации, 3 монографии)

* Clinical trials: <http://cryotechnomed.com/therapeutic-hypothermia/>

* Reviews: <http://cryotechnomed.com/therapeutic-hypothermia/>

We are ready for cooperation

Galina Repina

Leading Marketing Specialist

WhatsApp: +7 915 421 13 50

Telegram: https://t.me/galina_repina

E-mail: neurosafe@mail.ru

Site: www.neurosafe.ru

